These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 29959803)

  • 1. Real-life efficacy and safety of secukinumab: results from a tertiary hospital in Greece.
    Tsentemeidou A; Sotiriou E; Vakirlis E; Sideris N; Papadimitriou I; Lazaridou E; Ioannides D
    J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):e50-e51. PubMed ID: 29959803
    [No Abstract]   [Full Text] [Related]  

  • 2. Secukinumab survival and long-term efficacy in patients with plaque psoriasis: real-life data from a tertiary hospital in Greece.
    Sotiriou E; Tsentemeidou A; Vakirlis E; Sideris N; Ioannides D
    J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):e82-e84. PubMed ID: 30176180
    [No Abstract]   [Full Text] [Related]  

  • 3. Efficacy of ixekizumab in patients with resistance or incomplete response to secukinumab.
    Hegazy S; Konstantinou MP; Bulai Livideanu C; Tauber M; Paul C
    J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):e338-e341. PubMed ID: 31001858
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical outcomes in patients on secukinumab (Cosentyx
    Sears AV; Szlumper C; Liu KW; Smith CH; Barker JNWN; Pink AE
    J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):e89-e91. PubMed ID: 30198598
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term continuation with secukinumab in psoriasis: association with patient profile and initial psoriasis clearance.
    Ferrières L; Konstantinou MP; Bulai Livideanu C; Hegazy S; Tauber M; Amelot F; Paul C
    Clin Exp Dermatol; 2019 Oct; 44(7):e230-e234. PubMed ID: 31055846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful Use of Secukinumab in Various Scenarios of Psoriasis.
    Chhabra G; Verma P; Khunger N
    Skinmed; 2020; 18(5):274-276. PubMed ID: 33160436
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of secukinumab in psoriasis patients with latent tuberculosis infection.
    Machado Á; Abreu M; Torres T
    Eur J Dermatol; 2020 Dec; 30(6):740-741. PubMed ID: 33237033
    [No Abstract]   [Full Text] [Related]  

  • 8. A prospective multicenter study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients.
    Ortiz-Salvador JM; Saneleuterio-Temporal M; Magdaleno-Tapial J; Velasco-Pastor M; Pujol-Marco C; Sahuquillo-Torralba A; Mateu-Puchades A; Pitarch-Bort G; Marí-Ruiz JI; Mataix-Díaz J; Montesinos-Villaescusa E; Miralles-Botella J; García-Fernández L; Martorell-Calatayud A; Belinchón-Romero I; Sánchez-Carazo JL; Pérez-Ferriols A
    J Am Acad Dermatol; 2019 Aug; 81(2):427-432. PubMed ID: 30872150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical experience of ixekizumab in the treatment of patients with history of chronic erythrodermic psoriasis who failed secukinumab: a case series.
    Lo Y; Tsai TF
    Br J Dermatol; 2019 Nov; 181(5):1106-1107. PubMed ID: 31145806
    [No Abstract]   [Full Text] [Related]  

  • 10. IL-17 inhibitors for psoriasis.
    Paek SY; Frieder J; Kivelevitch D; Menter MA
    Semin Cutan Med Surg; 2018 Sep; 37(3):148-157. PubMed ID: 30215631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of ixekizumab in a group of 16 elderly patients with psoriasis over a 1-year period.
    Megna M; Cinelli E; Balato A; Gallo L; Fabbrocini G
    J Eur Acad Dermatol Venereol; 2020 Mar; 34(3):e152-e153. PubMed ID: 31715054
    [No Abstract]   [Full Text] [Related]  

  • 12. Response to ixekizumab in a patient of psoriasis with secondary failure to secukinumab.
    Mittal S
    Indian J Dermatol Venereol Leprol; 2021; 87(1):119-121. PubMed ID: 33037161
    [No Abstract]   [Full Text] [Related]  

  • 13. The successful treatment with ixekizumab in a multi-failure psoriasis patient.
    Azevedo A; Torres T
    Dermatol Online J; 2018 Sep; 24(9):. PubMed ID: 30677837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mild therapeutic response of alopecia areata during treatment of psoriasis with secukinumab.
    Pagnanelli G; Cavani A; Canzona F; Mazzanti C
    Eur J Dermatol; 2020 Oct; 30(5):602-603. PubMed ID: 33185532
    [No Abstract]   [Full Text] [Related]  

  • 15. First emergence of pyoderma gangraenosum, palmoplantar pustulosis and sacroiliitis in a psoriasis patient associated with switching from secukinumab to brodalumab.
    Sadik CD; Thieme M; Zillikens D; Terheyden P
    J Eur Acad Dermatol Venereol; 2019 Nov; 33(11):e406-e407. PubMed ID: 31131924
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK.
    Johansson EC; Hartz S; Kiri SH; Kumar G; Svedbom A
    J Med Econ; 2018 Aug; 21(8):810-820. PubMed ID: 29873270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Body Weight on Risk-Benefit and Dosing Regimen Recommendation of Secukinumab for the Treatment of Moderate to Severe Plaque Psoriasis.
    Lee JE; Wang J; Florian J; Wang YM; Kettl D; Marcus K; Woitach A
    Clin Pharmacol Ther; 2019 Jul; 106(1):78-80. PubMed ID: 31188469
    [No Abstract]   [Full Text] [Related]  

  • 18. Real-world single-center experience with 10 cases of generalized pustular psoriasis successfully treated with ixekizumab.
    Nagata M; Kamata M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Sugiura K; Tada Y
    J Am Acad Dermatol; 2020 Mar; 82(3):758-761. PubMed ID: 31560979
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and safety of secukinumab in treating moderate to severe plaque psoriasis in two real-world Canadian dermatology clinics: a multicenter retrospective study.
    Georgakopoulos JR; Ighani A; Zhou LL; Yeung J
    J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e32-e34. PubMed ID: 28695989
    [No Abstract]   [Full Text] [Related]  

  • 20. No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis.
    Bokor-Billmann T; Schäkel K
    J Dermatolog Treat; 2019 May; 30(3):216-220. PubMed ID: 30051725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.